World Book DayWorld Book Day

Immune Checkpoint Inhibitors in Cancer, 1st Edition

Author :
Edited by Fumito Ito, MD, PhD and Marc Ernstoff, MD
Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to ...view more

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research.

ISBN :
9780323549486
Publication Date :
22-08-2018
Add to Cart

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research.


Key Features
  • Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages.
  • Helps you translate current research and literature into practical information for daily practice.
  • Presents information logically organized by disease site.
  • Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks.
  • Consolidates today’s available information on this timely topic into one convenient resource.

Author Information
Edited by Fumito Ito, MD, PhD, Associate Professor of Oncology, Department of Surgical Oncology, Member, Center for Immunotherapy, Roswell Park Cancer Institute; Associate Professor of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York; Marc Ernstoff, MD, Professor and Chair, Department of Medicine, Senior Vice President for Clinical Investigation, The Katherine Anne Gioia Chair of Medicine, Roswell Park Cancer Institute and Chief, Division of Oncology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffaclo, New York